TGM2 and systemic lupus erythematosus: Consistent with pre‐behavioral observations, the TGM2 overexpression group (AAV‐Tgm2) had a significantly lower rate of SLE events (p < 0.01) and a significantly shorter cumulative duration of epileptiform discharges (p < 0.05) when compared with the control group (Con‐AAV‐Tgm2) (Figure 2P,Q).